

## DAFTAR PUSTAKA

1. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers (Basel)*. 2021 Aug 25;13(17):4287.
2. Rahmatya A, Khambri D, Mulyani H. Hubungan usia dengan gambaran klinikopatologi kanker payudara di bagian bedah RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2015;4(2):478–84.
3. Hasnita Y, Harahap WA, Defrin D. Pengaruh Faktor Risiko Hormonal pada Pasien Kanker Payudara di RSUP. Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2019;8(3):522–8.
4. Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. *Breast Cancer Res Treat*. 2013 Jul 27;140(1):93–104.
5. Soediro R, Nugroho RS, Gondhowiardjo SA, Djoerban Z, Poetiray EDC. Karakteristik Subtipe Kanker Payudara Berdasarkan Status Hormonal dan Her-2. Vol. 1, *Radioterapi & Onkologi Indonesia*. 2010.
6. Rahma Amtiria H, Khairun D, Berawi N. Peran Human Epidermal Growth Factor Receptor-2 pada Kanker Payudara. Vol. 5, *J Agromedicine Unila* |. 2018.
7. Cancer Stat Facts: Female Breast Cancer Subtypes [Internet]. [cited 2023 Oct 10]. Available from: <https://seer.cancer.gov/statfacts/html/breast-subtypes.html>
8. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. *Clinical Cancer Research*. 2003;9(14):5078–84.
9. Lal P, Tan LK, Chen B. Correlation of HER-2 Status With Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast Carcinomas. *Am J Clin Pathol*. 2005 Apr 1;123(4):541–6.
10. Giuliano M, Trivedi M V., Schiff R. Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. *Breast Care*. 2013;8(4):256–62.
11. Guo S, Sonenshein GE. Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. *Mol Cell Biol*. 2004 Oct 1;24(19):8681–90.

12. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer. *JNCI Journal of the National Cancer Institute*. 2003 Jan 15;95(2):142–53.
13. Huang HJ. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. *J Clin Pathol*. 2005 Jun 1;58(6):611–6.
14. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. *Proceedings of the National Academy of Sciences*. 2006;103(20):7795–800.
15. McKee T, McKee J. *Biochemistry: The molecular basis of life*. 5th. New York: Oxford University Press; 2011.
16. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. *Biol Res*. 2017 Dec 2;50(1):33.
17. Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers (Basel)*. 2022 May 23;14(10):2569.
18. WHO. Indonesian fact sheets [Internet]. 2021 [cited 2023 Aug 3]. Available from: <https://gco.iarc.fr>
19. Laporan Hasil Riset Kesehatan Dasar [Internet]. [cited 2022 Sep 9]. Available from: <https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-risikesdas/>
20. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 2018 Jun;5(2):77–106.
21. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. *The Lancet*. 2005 May;365(9472):1727–41.
22. Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses' health study. *Breast Cancer Res Treat*. 2012 Jun 19;133(3):1097–104.
23. Allison KH. Molecular Pathology of Breast Cancer. *Am J Clin Pathol*. 2012 Dec 1;138(6):770–80.
24. Shahbandi A, Nguyen HD, Jackson JG. TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. *Trends Cancer*. 2020 Feb;6(2):98–110.

25. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. *Lancet Oncol.* 2013 Sep;14(10):1009–19.
26. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst.* 2002 Apr 17;94(8):606–16.
27. Giordano SH. Breast Cancer in Men. *New England Journal of Medicine.* 2018 Jun 14;378(24):2311–20.
28. Benz CC. Impact of aging on the biology of breast cancer. *Crit Rev Oncol Hematol.* 2008 Apr;66(1):65–74.
29. McGuire A, Brown JAL, Malone C, McLaughlin R, Kerin MJ. Effects of age on the detection and management of breast cancer. *Cancers (Basel).* 2015 May 22;7(2):908–29.
30. Baglia ML, Tang MTC, Malone KE, Porter P, Li CI. Family History and Risk of Second Primary Breast Cancer after In Situ Breast Carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2018 Mar;27(3):315–20.
31. Wu HC, Do C, Andrulis IL, John EM, Daly MB, Buys SS, et al. Breast cancer family history and allele-specific DNA methylation in the legacy girls study. *Epigenetics.* 2018 Mar 4;13(3):240–50.
32. Çelik A, Acar M, Moroski Erkul C, Gunduz E, Gunduz M. Relationship of Breast Cancer with Ovarian Cancer. In: *A Concise Review of Molecular Pathology of Breast Cancer.* InTech; 2015.
33. Ghafoor A, Samuels A, Jemal A. American Cancer Society breast cancer facts & figures. *Breast cancer facts and figures.* 2004;1–27.
34. Albrektsen G, Heuch I, Hansen S, Kvåle G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. *Br J Cancer.* 2005 Jan 14;92(1):167–75.
35. Husby A, Wohlfahrt J, Øyen N, Melbye M. Pregnancy duration and breast cancer risk. *Nat Commun.* 2018 Oct 23;9(1):4255.
36. Innes KE, Byers TE. Preeclampsia and breast cancer risk. *Epidemiology.* 1999 Nov;10(6):722–32.
37. Orgéas CC, Hall P, Rosenberg LU, Czene K. The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer. *Breast Cancer Research.* 2008 Dec 16;10(6):R107.



38. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. *Int J Biol Sci.* 2017;13(11):1387–97.
39. Washbrook E. Risk factors and epidemiology of breast cancer. *Women's Health Medicine.* 2006;3(1):8–14.
40. Narod SA. Hormone replacement therapy and the risk of breast cancer. *Nat Rev Clin Oncol.* 2011;8(11):669–76.
41. Crandall CJ, Sehl ME, Crawford SL, Gold EB, Habel LA, Butler LM, et al. Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women. *Breast Cancer Research.* 2009 Aug 27;11(4):R51.
42. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N, et al. Sex steroid-producing enzymes in human breast cancer. *Endocr Relat Cancer.* 2005 Dec;12(4):701–20.
43. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. *Oncologist.* 2003;8(4):307–25.
44. Hung MC, Lau YK. Basic science of HER-2/neu: a review. In: *Seminars in oncology.* 1999. p. 51–9.
45. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, et al. *HER2* and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. *New England Journal of Medicine.* 2006 May 18;354(20):2103–11.
46. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *Arch Pathol Lab Med.* 2014 Feb 1;138(2):241–56.
47. Wada R, Yagihashi S, Naito Z. mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer. *Mol Med Rep.* 2016 Dec;14(6):5104–10.
48. Agersborg S, Mixon C, Nguyen T, Aithal S, Sudarsanam S, Blocker F, et al. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification. *Breast Cancer Res Treat.* 2018;170:321–8.
49. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. *New England Journal of Medicine.* 2006;354(20):2103–11.

50. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szólósi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. *Pathology and Oncology Research*. 1999;5(4):255–71.
51. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. *Mol Biol Int*. 2014;2014.
52. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Discov*. 2014;13(2):140–56.
53. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. *Arch Pathol Lab Med*. 2020 May 1;144(5):545–63.
54. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. *Cell*. 1995;83(6):835.
55. Klinge CM. Estrogen receptor interaction with estrogen response elements. *Nucleic Acids Res*. 2001 Jul 15;29(14):2905–19.
56. Ibrahim M, Bartlett JMS, Miller K, Jasani B. Breast Cancer Biomarkers: Prognostic and Predictive Value and External Quality Assurance. In: *Breast Pathology*. Elsevier; 2011. p. 306–16.
57. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med*. 2010 Jul;134(7):e48-72.
58. Björnström L, Sjöberg M. Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target Genes. *Molecular Endocrinology*. 2005 Apr 1;19(4):833–42.
59. Bowers LW, Cavazos DA, Maximo IXF, Brenner AJ, Hursting SD, DeGraffenried LA. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. *Breast Cancer Research*. 2013;15(4):1–13.
60. Tan H, Yi L, Rote NS, Hurd WW, Mesiano S. Progesterone Receptor-A and -B Have Opposite Effects on Proinflammatory Gene Expression in Human Myometrial Cells: Implications for Progesterone Actions in

Human Pregnancy and Parturition. *J Clin Endocrinol Metab.* 2012 May;97(5):E719–30.

61. Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. *Drug Des Devel Ther.* 2022 Jan;Volume 16:305–14.
62. Iqbal B, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. *Medical Journal of Dr DY Patil University.* 2016;9(6):674.
63. Giangrande PH, Pollio G, McDonnell DP. Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor. *Journal of Biological Chemistry.* 1997 Dec;272(52):32889–900.
64. Lake DE, Hudis C. Aromatase inhibitors in breast cancer: an update. *Cancer Control.* 2002;9(6):490–8.
65. Lan K, Lu C, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. *Ann N Y Acad Sci.* 2005;1059(1):70–5.
66. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med.* 2011;62:233–47.
67. Lee JR, Zava D, Hopkins V. *Kanker Payudara Pencegahan dan Pengobatannya.* Jakarta: Daras Books. 2008;
68. Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. *Can Med Assoc J.* 2007 May 8;176(10):1429–34.
69. Firasi AA, Yudhanto E. Hubungan usia terhadap derajat diferensiasi kanker payudara pada wanita. *Diponegoro Medical Journal (Jurnal Kedokteran Diponegoro).* 2016;5(4):327–36.
70. Diahpradnya Oka Partini P, Nirvana IW, Anda Tusta Adiputra P. Karakteristik kanker payudara usia muda di Subbagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah tahun 2014-2016. *Intisari Sains Medis.* 2018 Apr 30;9(1).
71. Yulianti I, Santoso HS, Sutiningsih D. Faktor-faktor risiko kanker payudara (studi kasus pada Rumah Sakit Ken Saras Semarang). *Jurnal Kesehatan Masyarakat.* 2016;4(4):401–9.
72. Suparman E, Suparman E. Peran Estrogen dan Progesteron terhadap Kanker Payudara. *Biomedik (JBM).* 2014 Dec 15;6(3).



73. Surbakti E. Hubungan Riwayat Keturunan Dengan Terjadinya Kanker Payu-dara Pada Ibu Di RSUP H. Adam Malik Medan. *None*. 2013;1:160007.
74. Ilham Malik Fajar, Yusuf Heriady, Hidayat Wahyu Aji. Karakteristik Usia, Gambaran Klinis dan Histopatologi Pasien Kanker Payudara di RSUD Al-Ihsan Provinsi Jawa Barat Periode Januari 2018 - Oktober 2020. *Jurnal Riset Kedokteran*. 2021 Dec 31;1(2):85–91.
75. Satya Wangsa IGMSW, Niryana IW, Anda Tusta Adiputra PATA, Pande Arista Dewi NPA. Gambaran stadium dan jenis histopatologi kanker payudara di Subbagian Bedah Onkologi RSUP Sanglah Denpasar tahun 2015-2016. *Intisari Sains Medis*. 2018 Apr 30;9(1).
76. Alfalah R. Jenis Histopatologi Berdasarkan Stadium Pada Pasien Kanker Payudara di RSUCM Aceh Utara Tahun 2020. *Matriks Jurnal Sosial dan Sains*. 2022 Jul 14;4(1):21–30.
77. Albasri A, Hussainy AS, Sundkji I, Alhujaily A. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia. *Saudi Med J*. 2014;35(12):1489.
78. Abiltayeva A, Moore MA, Myssayev A, Adylkhanov T, Baissalbayeva A, Zhabagin K, et al. Clinical, histopathological and molecular characteristics of metastatic breast cancer in North-Eastern Kazakhstan: a 10 year retrospective study. *Asian Pac J Cancer Prev*. 2016;17(10):4797.
79. Ilham Malik Fajar, Yusuf Heriady, Hidayat Wahyu Aji. Karakteristik Usia, Gambaran Klinis dan Histopatologi Pasien Kanker Payudara di RSUD Al-Ihsan Provinsi Jawa Barat Periode Januari 2018 - Oktober 2020. *Jurnal Riset Kedokteran*. 2021 Dec 31;1(2):85–91.
80. Pandit P, Patil R, Palwe V, Gandhe S, Patil R, Nagarkar R. Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. *Eur J Breast Health*. 2020 Jan;16(1):39–43.
81. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clinical cancer research*. 2004;10(16):5367–74.
82. Tubtimhin S, Promthet S, Suwanrungruang K, Supaattagorn P. Molecular subtypes and prognostic factors among premenopausal and postmenopausal Thai women with invasive breast cancer: 15 years follow-up data. *Asian Pac J Cancer Prev*. 2018;19(11):3167.
83. Mane A, Khatib KI, Deshmukh SP, Nag SM, Sane SP, Zade BP. A comparison of clinical features, pathology and outcomes in various

subtypes of breast cancer in Indian women. *J Clin Diagn Res.* 2015;9(9):PC01.

84. Elidrissi Errahhali M, Elidrissi Errahhali M, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. *BMC Womens Health.* 2017;17(1):1–11.
85. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol.* 2014;5(3):412.
86. Octovianus J, Djatmiko A. Hubungan Overekspresi HER-2/neu dengan Status Reseptor Hormonal dan Grading Histopatologi pada Penderita Karsinoma Payudara di RS Onkologi Surabaya. *Indonesian Journal of Cancer.* 2012;6(3).
87. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. *BMC Cancer.* 2011 Nov 14;11:486.
88. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. *Modern Pathology.* 2010 Feb;23(2):251–9.
89. Hosseini S, Shahbaziyan H, Razmjoo S, Jasemizade N. Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients. *Biosci Biotechnol Res Asia.* 2015 Dec 25;12(3):2221–5.
90. Shokouh TZ, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study. *Medicine.* 2015 Aug;94(32):e1359.
91. Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S, et al. Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya. *J Cancer.* 2012;3:421–31.
92. Liu X, Zheng Y, Qiao C, Qv F, Wang J, Ding B, et al. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics. *Diagn Pathol.* 2015 Dec 9;10(1):50.
93. Vaidyanathan K, Kumar P, Reddy C, Deshmane V, Somasundaram K, Mukherjee G. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. *Indian J Cancer.* 2010;47(1):8.



94. Ramadan SS, Yapicier O, Kihtir S, Erdemir A, Dogan TH, Uskent I, et al. Correlation of her 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma. *Turkish Journal of Pathology*. 2011;27(3):196.
95. Kolár Z, Murray PG, Zapletalová J. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression. *Neoplasma*. 2002;49(2):110–3.
96. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. *Biol Reprod*. 1998 Mar;58(3):627–32.
97. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. *Cancer Res*. 2001 Feb 1;61(3):903–7.
98. Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. *Br J Cancer*. 2010 Aug 27;103(4):475–81.
99. Bhagat VM, Jha BM, Patel PR. Correlation of hormonal receptor and Her-2/neu expression in breast cancer: a study at tertiary care hospital in south Gujarat. *National journal of medical research*. 2012;2(03):295–8.

